Pages that link to "Q27012963"
Jump to navigation
Jump to search
The following pages link to 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity (Q27012963):
Displaying 50 items.
- Aptamers: A Feasible Technology in Cancer Immunotherapy (Q26740303) (← links)
- NK Cell Subtypes as Regulators of Autoimmune Liver Disease (Q26741392) (← links)
- Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect (Q26775578) (← links)
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy (Q28066199) (← links)
- 4-1BB agonism: adding the accelerator to cancer immunotherapy (Q28079622) (← links)
- The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses (Q36940326) (← links)
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. (Q38666253) (← links)
- NK cells and cancer: you can teach innate cells new tricks. (Q38676458) (← links)
- Immunotherapy for advanced melanoma: future directions. (Q38711163) (← links)
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy (Q38775177) (← links)
- The potential roles of dopamine in malignant glioma (Q38780472) (← links)
- Programming the immune checkpoint to treat hematologic malignancies. (Q38806070) (← links)
- Combinatorial approach to cancer immunotherapy: strength in numbers (Q38852256) (← links)
- Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer (Q38899873) (← links)
- Delivering safer immunotherapies for cancer (Q39330984) (← links)
- Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. (Q40457683) (← links)
- Functional Detection of TNF Receptor Family Members by Affinity-Labeled Ligands (Q41192295) (← links)
- Editorial: Advances in Combination Tumor Immunotherapy (Q42047687) (← links)
- PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. (Q42253745) (← links)
- A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members (Q42378925) (← links)
- 4-1BB (CD137) and radiation therapy: A case report and literature review (Q43379703) (← links)
- Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. (Q46450905) (← links)
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'. (Q46527001) (← links)
- Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8 T Cells in an Adoptive Transfer Model of Cancer Immunotherapy (Q47259954) (← links)
- Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. (Q47595753) (← links)
- Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives (Q47986213) (← links)
- Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. (Q50187435) (← links)
- Aptamer Therapeutics in Cancer: Current and Future. (Q52347485) (← links)
- Immune checkpoint pathways in non-small cell lung cancer. (Q52581741) (← links)
- Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). (Q52683991) (← links)
- Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. (Q54734909) (← links)
- Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. (Q55036897) (← links)
- Tumor immunotherapy: New aspects of natural killer cells. (Q55107050) (← links)
- Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. (Q55386131) (← links)
- Update on the Treatment of Metastatic Urothelial Carcinoma. (Q55454917) (← links)
- A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity (Q56889692) (← links)
- Immuno-Oncology: Emerging Targets and Combination Therapies (Q56889817) (← links)
- The promise and challenges of immune agonist antibody development in cancer (Q56891562) (← links)
- Polycationic carbosilane dendrimer decreases angiogenesis and tumor-associated macrophages in tumor-bearing mice (Q57079914) (← links)
- Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab (Q58586476) (← links)
- Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9 (Q58700606) (← links)
- 4-1BB Signaling Promotes Alveolar Macrophages-Mediated Pro-Fibrotic Responses and Crystalline Silica-Induced Pulmonary Fibrosis in Mice (Q58754498) (← links)
- A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity (Q59136671) (← links)
- CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs (Q59800859) (← links)
- Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity (Q64052040) (← links)
- Switching on the green light for chimeric antigen receptor T-cell therapy (Q64066845) (← links)
- Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma (Q64254749) (← links)
- Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. (Q64886488) (← links)
- 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses (Q87981825) (← links)
- Crystal structure of the human 4-1BB/4-1BBL complex (Q88547220) (← links)